首页> 外文OA文献 >ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection

【2h】

ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection

机译：ABT-450，利托那韦，ombitasvir和dasabuvir在有治疗经验的HCV基因型1b感染患者中，无论是否接受病毒唑，均可达到97％和100％的持续病毒学应答

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

获取外文期刊封面目录资料

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Andreone, Pietro; Colombo, Massimo G; Enejosa, Jeffrey V; Koksal, Iftihar; Ferenci, Peter; Maieron, Andreas; Müllhaupt, Beat; Horsmans, Yves; Weiland, Ola; Reesink, Henk W; Rodrigues, Lino; Hu, Yiran B; Podsadecki, Thomas; Bernstein, Barry;
展开▼
作者单位

展开▼
年度 2014
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection [J] . AndreoneP., ColomboM.G., EnejosaJ.V., Gastroenterology . 2014,第2期

机译：ABT-450，利托那韦，ombitasvir和dasabuvir在有治疗经验的HCV基因型1b感染患者中，无论是否接受病毒唑，均可达到97％和100％的持续病毒学应答
2. Low Relapse Rate Leads to High Concordance of Sustained Virologic Response (SVR) at 12 Weeks With SVR at 24 Weeks After Treatment With ABT-450/Ritonavir, Ombitasvir, and Dasabuvir Plus Ribavirin in Subjects With Chronic Hepatitis C Virus Genotype 1 Infection in the AVIATOR Study [J] . Poordad Fred, Agarwal Kosh, Younes Ziad, Clinical infectious diseases . 2015,第4期

机译：低复发率导致AVR-450 / Ritonavir，Ombitasvir和Dasabuvir加Ribavirin治疗慢性丙型肝炎病毒基因型1感染者在治疗24周后与SVR在12周时持续病毒学应答（SVR）高度一致研究
3. Management of Hemoglobin Decrease in Patients Treated With ABT-450/Ritonavir/Ombitasvir and Dasabuvir With or Without Ribavirin in HCV Genotype 1-Infected Patients [J] . Rustgi Vinod, Bernstein David, Sepe Thomas, The American Journal of Gastroenterology . 2014,第Suppla2期

机译：接受或不接受利巴韦林的ABT-450 / Ritonavir / Ombitasvir和Dasabuvir治疗的HCV基因型1感染患者血红蛋白减少的管理
4. Patients with HCV/HIV Co-infection Achieving a Sustained Virological Response Following HCV Treatment with Peginterferon alfa-2a (PEGASYS) plus Ribavirin (COPEGUS) have Improved Health Related Quality of Life [C] . D.T. Dieterich, M. Rodriguez Torres, J.K. Rockstroh International AIDS Conference . 2004

机译：HCV / HIV的患者在用Peginterferon Alfa-2a（Pegasys）加上利巴韦林（Copegegs）后HCV治疗后实现持续的病毒学反应，具有改善的健康相关的生活质量
5. Baseline Toronto HCC Risk Index (THRI) and Albumin Predict Low Risk of Hepatocellular Carcinoma (HCC) after Sustained Virological Response (SVR) in HCV Infection [D] . Lau, Jason. 2019

机译：基线多伦多HCC风险指数（THRI）和白蛋白预测HCV感染持续病毒响应（SVR）后肝细胞癌（HCC）的低风险
6. Original article: Daclatasvir plus sofosbuvir with or without ribavirin achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort [O] . Tania M Welzel, Jörg Petersen, Kerstin Herzer, -1

机译：原始文章：达卡他韦加索非布韦有或没有利巴韦林在现实世界中的HCV感染和晚期肝病患者中均获得了较高的持续病毒学应答率
7. ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection [O] . Andreone, Pietro, Colombo, Massimo G., Enejosa, Jeffrey V., 2014

机译：ABT-450，利托那韦，ombitasvir和dasabuvir在有治疗经验的HCV基因型1b感染患者中，无论是否接受病毒唑，均可达到97％和100％的持续病毒学应答

ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection

著录项

引文网络

相似文献

相关主题

期刊订阅